Potential of cycloaddition reactions to generate cytotoxic metal drugs in vitro by Murray, Benjamin S.. et al.
 1 
The Potential of Cycloaddition Reactions to 
Generate Cytotoxic Metal Drugs In Vitro 
Benjamin S. Murray,* Stéphanie Crot, Sviatlana Siankevich, and Paul J. Dyson* 
Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL) 
CH-1015, Lausanne, Switzerland. 
ABSTRACT  
Severe general toxicity issues blight many chemotherapeutics utilised in the treatment of cancers, 
resulting in the need for more selective drugs able to exert their biological activity at only the 
required location(s).  Toward this aim, we report the development of an organometallic 
ruthenium compound, functionalised through a η6-bound arene ligand with a bicyclononyne 
derivative, able to participate in strain promoted cycloaddition reactions with tetrazines.  We 
show that combination of the ruthenium compound with a di-tetrazine in biological media results 
in the in situ formation of a dinuclear molecule that is more cytotoxic toward cancer cells than 
the starting mononuclear ruthenium compound and tetrazine components.  Such an approach 
may be extended to in vivo applications to construct a cytotoxic metallodrug at a tumour site – 
providing a novel approach toward the turn-on cytotoxicity of metallodrugs in the treatment of 
cancer.  
INTRODUCTION  
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Many widely used anticancer drugs act through interactions with targets that are not unique to 
cancer cells.  This lack of specificity results in the indiscriminate action of highly cytotoxic 
chemotherapeutics on cancer cells and healthy cells alike and often results in severe side 
effects.1,2  Such lack of specificity is present across virtually every class of chemotherapeutic and 
has spurred increased efforts towards the development of more selective drugs and protocols for 
the treatment of cancer.  One such route to circumvent general toxicity problems would be the 
synthesis of a cytotoxic compound at a tumor site/in a cancer cell, which would ensure only cell 
death at the desired location.  Toward this aim, we chose to devise ruthenium-based 
organometallics from which a more cytotoxic product could be constructed in a physiological 
environment. 
 Ruthenium-based anticancer compounds constitute a flourishing area of research with 
many novel compounds having being developed3 in attempts to emulate the clinical success of 
the platinum-based drug cisplatin and subsequent derivatives4,5 against various cancer types 
whilst avoiding their associated severe side effects.  RuIII prodrugs that are reduced to more 
active RuII species in vivo have shown particular promise and two of these, NAMI-A and 
KP1019, have progressed to clinical trials.6  Stable RuII compounds in the form of 
organometallic species have also proved to be interesting with examples possessing a wide range 
of activities so far reported.7,8   The ‘piano stool’ structure of these organometallics offers 
considerable scope for structural modification where each ligand may be modulated to allow 
access to diverse compounds endowed with a wide range of functionality, thus providing an ideal 
platform for the development of prospective new chemotherapeutics.7-9  Our research has 
focused on the [Ru(η6-arene)Cl2(PTA)] (RAPTA) family of organometallics which exhibit low 
cytotoxicity and promising antimetastatic activity in vivo.10  As part of a recent effort to develop 
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and study dinuclear RAPTA analogues we investigated the anticancer properties of a small series 
of arene-linked dinuclear RAPTA analogues (Figure 1).11  These dinuclear compounds are 
considerably more cytotoxic toward cancer cells (IC50 <15 μM) compared to the negligible 
cytotoxicity of their mononuclear analogues (IC50 >300 μM).  Further platinum and ruthenium-
based dinuclear metallodrugs (e.g. the platinum compound BBR361012 and dinuclear ruthenium 
organometallics linked via maltol-derive linkers13) have also been shown to be significantly more 
cytotoxic than mononuclear analogues toward tumorigenic cell lines.  In light of these 
observations we postulated whether a dinuclear organometallic RuII complex could be formed 
from mononuclear RAPTA species in situ in a cellular environment, thus providing a route via 
which compounds of low cytotoxicity could be transformed into more cytotoxic species. Such a 
mechanism could afford a route to tumor selective cytotoxic agents.   
 
  
 
 
 
 
In this context we were interested in the incorporation of bioorthogonal functionality able 
to participate in strain-promoted cycloaddition reactions into the arene ligand of the RAPTA 
structure.  Strain-promoted cycloaddition reactions have emerged as a powerful tool for the 
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modification and imaging of molecules of interest in a biological environment.14  The strain-
promoted reactions between cyclooctynes and azides,15 and between trans-cyclooctene16 or 
cyclooctynes17,18 with tetrazines, have been at the forefront of recent advances in this field, 
resulting in a range of extremely fast bioorthogonal reactions (e.g. a rate constant for reaction 
between a trans-cyclooctene and a tetrazine of 22000 M-1 s-1 in CD3OD at 298 K has been 
reported19).  Strain-promoted cycloaddition reactions have been widely employed in cell-based 
studies to selectively image biomolecules of interest including cell-surface glycans20 and 
intracellular and cell surface proteins,21,22 and in imaging of glycans in live developing 
zebrafish23 and tumor imaging in live mice.24 In addition, strain-promoted cycloaddition 
reactions with a trans-cyclooctene (TCO) have been employed in the development of a novel 
doxorubicin (Dox) prodrug strategy based on elimination of Dox from a TCO-Dox conjugate 
upon reaction with a tetrazine.25 
 We envisaged utilising this chemistry to link two mononuclear, non-toxic organometallic 
ruthenium compounds to form a cytotoxic dinuclear compound in situ in a cellular environment.  
Such ‘turn-on’ cytotoxicity could be utilised in the context of cancer treatment through the 
spatial localisation of the reactive components either in an extracellular or intracellular 
environment followed by their reaction to yield the cytotoxic product.  Recent reports have 
demonstrated the cycloaddition of bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN) derivatives with 
tetrazine derivates with fast reaction kinetics (1245 ± 45 M-1 s-1, 55:45 MeOH:H2O, 298 K).
17  
Given the fast reaction kinetics, commercial availability of BCN-derivatives and the synthetic 
accessibility of tetrazine precursor 3,26 we decided to explore whether the combination of a 
BCN-containing RAPTA derivative with a di-tetrazine linker molecule would yield a more 
cytotoxic dinuclear ruthenium complex in a cellular environment. 
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Here, we describe the incorporation of a bicyclo[6.1.0]non-4-yn-9-ylmethanol derivative 
into the η6-arene ligand of an organometallic RuII-arene (RAPTA-type) complex and 
demonstrate its conjugation to mono- and di-tetrazine derivatives.  The BCN-containing RAPTA 
and the tetrazines conjugate rapidly and in quantitative yield to afford mononuclear and 
dinuclear ruthenium compounds.  Cytotoxicity assays reveal that this conjugation ‘activates’ the 
mononuclear RAPTA-BCN derivative to afford a more potent dinuclear compound, providing a 
novel route toward the in situ ‘turn-on’ enhancement of cytotoxicity. 
RESULTS AND DISCUSSION  
BCN-containing RAPTA, 2, was accessed through the reaction of N-(1R,8S,9s)-
bicyclo[6.1.0]non-4-yn-9-ylmethyloxycarbonyl 1,5-diaminopentane (BCN-C5-NH2) with the 
carboxylic acid-containing RAPTA, 1, using the coupling agent O-(benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium tetrafluoroborate (TBTU) with N,N-diisopropylethylamine (DIPEA) in DMF 
(Scheme 1), based on a recently reported route.11 The ethylene-glycol functionalised tetrazine-
precursors 4 and 6 were prepared by reaction of 3 and 2-(2-(2-methoxyethoxy)ethoxy)acetic acid 
(1:1 ratio) or 3,6,9-trioxaundecanedioic acid (2:1 ratio), respectively, using TBTU and DIPEA in 
DMF.  The resulting tetrazine precursors were then oxidized using DDQ in toluene; 
chromatographic separation on silica gel yielded the mono-tetrazine and di-tetrazine analogue 5 
and 7 respectively.   
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All compounds were characterized by 1H and 13C NMR spectroscopy, high-resolution mass 
spectrometry and HPLC/LC-MS.   
Tetrazines possess a range of stabilities in biological media, with the general trend being 
the more electron-rich the tetrazines the greater the stability, but the lower the reactivity toward 
cycloaddition reactions.27  We examined the stability of tetrazines 5 and 7 in both phosphate-
buffered saline (PBS, 50 mM) and in RPMI cell culture media containing 10 % fetal bovine 
serum (FBS) at 37°C by monitoring the change in absorbance at 515 nm for 5 and 525 nm for 7.  
For 5 in PBS, the decrease in absorbance at 515 nm fit well to a single exponential decay 
function revealing a half-life of 82 min (Figure S16).  1H NMR spectra of 5 in PBS revealed the 
complete loss of the original tetrazine resonances over this time with concomitant colour change 
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mono- and di-tetrazines 5 and 7. 
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of the solution from red to yellow (Figure S17).  Ditetrazine 7 is considerably more stable in PBS 
with a more gradual linear loss of absorbance at 525 nm (Figure S18) and the half life for this 
compound was found to be significantly longer (>23 h).  Analysis of 5 in RPMI with 10% FBS 
by UV-Vis was more complex (Figure S19); following an initial induction period a rapid loss in 
absorbance at 515 nm is observed, reaching a minimum value after approximately 50 min.  This 
decay in absorbance did not fit well to various decay functions – indicative of multiple processes 
which presumably include decomposition of the tetrazine and reaction with components on the 
RPMI/FBS solution.  Analysis of 7 in RPMI + 10% FBS was complicated by the slow formation 
of a precipitate.  The reactivity of the tetrazines reported here follows observations of high 
reactivity of tetrazines with similar core structures in PBS and FBS solutions.27 However, given 
that the reactions between 2 and 5 or 7 are extremely fast compared to tetrazine decomposition in 
PBS or RPMI media cytotoxicity studies were undertaken. 
The reaction of the BCN-containing RAPTA derivative, 2, with the mono- and di-
tetrazines 5 and 7 was investigated in aqueous solution (Scheme. 2).  
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1H NMR spectroscopy was used to probe the reaction between tetrazines 5 and 7 and the BCN-
RAPTA adduct, 2, in PBS (50 mM in D2O, pD 7.65, 298 K).  On addition of 2 (0.2 ml, 12 mM) 
to a solution of 5 (0.2 ml, 12 mM) evolution of gas was immediately observed, indicating the 
release of N2.  
1H NMR of the solution before and after (2 min) addition of 2 showed complete 
transformation of the tetrazine resonances to product peaks consistent with the sole formation of 
the desired cycloaddition product 8 (Figure 2).   
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Reaction of 2 with the di-tetrazine, 7, under the same conditions, also led to the desired 
dinuclear cycloaddition product 9 in quantitative yield (Figure S13).  In addition, the reaction 
between 2 and 7 was also performed at a concentration of 20 μM in H2O (unbuffered, 310 K, 12 
h).  Analysis of the reaction products by ESI-MS revealed the complete conversion of the 
starting components to 9, highlighting the utility of the cycloaddition reaction at very low 
concentrations.  The reaction between 2 and tetrazines 5 and 7 was too fast to monitor by UV-
Vis spectroscopy, consistent with the high rate constants for the reaction between related 
N
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Figure 2. 1H NMR spectra (400 MHz) of the reaction between 2 (12 mM) and 5 
(12 mM) in PBS (50 mM, D2O, pD 7.65, 298 K).  1) 5 alone. 2) 5 following the 
addition of 2 (1 eq) (2 min). 3) after 20 min. 4) after 105 min.  Aromatic 
resonances of tetrazine 5 and the cycloddition product 8 are labelled. 
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tetrazines and BCN-derivatives previously reported (1245 M-1 s-1 in 55:45 MeOH:H2O, 298 K)
17  
and the expectation that these rate constants are enhanced in purely aqueous conditions. 
 To assess the potential of the cycloaddition reactions with tetrazines to modify the 
structure (and biological activity) of 2 in cellular media the cytotoxicities of 2, 5 and 7 were 
evaluated in the A2780 cell line, as were the cycloaddition products 8 and 9 preformed through 
incubation of 2 and 5 or 7 in H2O or by in situ formation of the dinuclear species in the cell 
culture (Table 1).  The cytotoxicities of tetrazines 5 and 7 were negligible with both possessing 
an IC50 value of >400 μM.  The BCN-RAPTA complex 2 is more cytotoxic with an IC50 value of 
12 μM.  The IC50 values of the preformed cycloaddition compounds 8 and 9 are different to that 
of 2.  The dinuclear compound 9 is, as anticipated, more cytotoxic than the mononuclear 
complex, with a 2.4 fold decrease in IC50 value (with respect to Ru concentration) whilst the 
preformed mononuclear compound 8 is less cytotoxic.  The dinuclear cycloaddition product, 9, 
formed in situ has a similar IC50 to that when preformed, 2.5 and 2.6 μM respectively.  In 
contrast, the mononuclear complex 8 formed in situ is more cytotoxic than the preformed 
mononuclear compound with an IC50 value of 5.7 μM compared to the IC50 value of >20 μM for 
the preformed adduct.  The increased cytotoxicity of 8 formed in situ potentially indicates that 
the individual components 2 and 5 may be separately internalised, transported then combine in 
an intracellular location different to the intracellular destinations of preformed 8, leading to 
different biological activity. 
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Table 1.   IC50 values of Ru
II compounds 2, 8 and 9 and tetrazines 5 and 7 in the human ovarian 
carcinoma (A2780) cell line after 72 h (MTT assay). 
Compound IC50 (complex 
concentration, μM) 
A2780 cell line 
2 
5 
7 
8 (preformed) 
9 (preformed) 
8 (formed in situ) 
9 (formed in situ) 
12 ± 1 
> 400 
> 400 
> 20 
2.5 ± 0.4 
5.7 ± 1 
2.6 ± 0.2 
 
CONCLUSIONS  
In conclusion, in this proof-of-principle study we have shown that through the development of a 
RAPTA compound containing a bicyclononyne derivative appended to the arene ligand, and its 
strain-promoted cycloaddition reaction with a di-tetrazine in biological media, a more cytotoxic 
dinuclear compound can be accessed.  Moreover, the higher cytotoxicity of the large 
mononuclear complex 8 formed in situ, relative to the preformed sample, potentially indicates 
that the cycloaddition reactions may proceed inside the cell leading to the modified cytotoxicity 
of the complex.  For in vivo applications it may be envisaged that chemotherapy with such 
cycloaddition-based systems may proceed via the sequential treatment with the ruthenium 
complex, e.g. 2, then once accumulation had reached sufficient levels the cycloaddition partner, 
e.g. 5 or 7, would then be administered to initiate a cytotoxic response.  Much work is needed to 
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optimize such a study, including the development of a less cytotoxic ruthenium component in 
place of 2.  However, our work demonstrates that the combination of functionalised tetrazines 
and RAPTA derivatives containing functionality able to participate in strain-promoted 
cycloaddition reactions holds significant potential in the development of organometallic systems 
with turn-on cytotoxicity.  This approach could be extended to many other classes of drug and 
drug-like compounds. 
EXPERIMENTAL SECTION  
Materials:  All commercially purchased materials were used as received.  N-(1R,8S,9s)-
bicyclo[6.1.0]non-4-yn-9-ylmethyloxycarbonyl 1,5-diaminopentane (BCN-C5-NH2) was 
purchased from SynAffix (Oss, Netherlands). Dichloromethane, diethyl ether and toluene were 
dried and degassed prior to use using a PureSolv solvent purification system (Innovative 
Technology INC).  N'N-dimethylformamide (99.8%, Extra Dry, Acroseal®) and acetone (99.8%, 
Extra Dry, Acroseal®) were obtained from Acros Organics and methanol (anhydrous, 99.8%) 
was purchased from Sigma-Aldrich. H2O was obtained from a Milli-Q Integral 5 purification 
system.  Thin-layer chromatography was carried out on silica plates (Merck 5554), 
visualised under UV irradiation (254 nm), with iodine staining or using potassium permanganate 
dip.  Where required, compounds were purified using either manual chromatography using silica 
gel (SiliCycle R12030B) or a Varian 971-FP flash chromatography system using pre-packaged 
silica gel columns (Luknova). Instrumentation and methods:  1H, 13C and 31P NMR spectra 
were recorded on a Bruker Avance II 400 spectrometer (1H at 400 MHz, 13C at 101 MHz and 31P 
at 162 MHz).  Spectra are referenced internally to residual solvent peaks (D2O: 
1H δ 4.79, 13C δ 
unreferenced; DMSO-d6: 
1H δ 2.50, 13C δ 39.52; CDCl3: 1H δ 7.26, 13C δ 77.16); 31P NMR 
spectra are reported relative to an 85% H3PO4 external reference.  Electrospray-ionisation mass 
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spectra (ESI-MS) were acquired on a Q-Tof Ultima mass spectrometer (Waters) operated in the 
positive ionization mode and fitted with a standard Z-spray ion source equipped with the Lock-
SprayTM interface.  The samples were diluted in CH3CN/H2O/HCOOH (50:49.9:0.1, ~10
-5 M) 
and 5 μl was introduced into the mass spectrometer by infusion at a flow rate of 20 μl/min with a 
solution of CH3CN/H2O/HCOOH (50:49.9:0.1).  Experimental parameters were set as follows: 
capillary voltage: 3.5 kV, sample cone: 35 V, source temperature: 80°C, desolvation 
temperature: 200°C, acquisition window: m/z 300-1500 in 1 s.  External calibration was carried 
out with a solution of phosphoric acid at 0.01% introduced through an orthogonal ESI probe.  
Data from the Lock-Spray were used to calculate a correction factor for the mass scale and 
provide accurate mass information of the analyte.  Data were processed using the MassLynx 4.1 
software.  LC-MS data was recorded on an AutoPrep system (Waters) equipped with: 2525 
binary gradient module, column/fluidics organizer, sample manager 2767, PDA detector and 
ZQ4000 ESI-MS.  Electrospray, positive ionization mode was employed with a cone voltage of 
25 volts, a source temperature of 100 °C and a mass range of m/z 200-1500 in 2 sec.  HPLC 
analysis was performed on an Agilent 1260 Infinity HPLC equipped with DAD detector; an 
Agilent Hi-Plex H, 300*7.7 column was utilised.  UV-Vis absorbance spectra were recorded on a 
JASCO V-550 UV/VIS spectrophotometer (using Spectra Manager software (version 1.53.01)) 
and also on a SpectroMax M5e multi-mode microplate reader (using SoftMax Pro software 
(version 6.2.2)).  Melting points were measured using a Stuart Scientific SMP3 apparatus and are 
uncorrected.  A SpectroMax M5e multi-mode microplate reader was used to record the 
absorbance of solutions contained in 96-well plates (using SoftMax Pro software (version 
6.2.2)).  
Synthesis. 
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Complex 111 and compound 326 were synthesized according to literature procedures.  
Complex 2:  N,N-diisopropylethylamine (DIPEA) (31 μl, 0.18 mmol) and O-(benzotriazol-1-yl)-
N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) (29 mg, 0.09 mmol) were added to a 
suspension of 1 (46 mg, 0.09 mmol) in DMF (1 ml) then the mixture was briefly sonicated then 
stirred for 5 min.  The yellow suspension was then added to a solution of N-(1R,8S,9s)-
bicyclo[6.1.0]non-4-yn-9-ylmethyloxycarbonyl 1,5-diaminopentane (BCN-C5-NH2) (25 mg, 0.09 
mmol) in DMF (1 ml) and the yellow suspension was stirred to form a yellow solution within 20 
min.  After 1 h the solution was filtered through cotton wool and the filtrate was diluted with 
acetone (15 ml) to yield a precipitate.  The suspension was cooled to 4°C and the filtrate isolated 
by centrifugation then concentrated under reduced pressure to a volume of 1 ml.  Diethyl ether 
(15 ml) was added to the filtrate to yield a solid (40 mg) that was collected by centrifugation.  
The filtrate was left at 4°C for 16 h to yield further solid that was also collected (18 mg).  The 
combined solids were dissolved in MeOH (2.5 ml), filtered then diethyl ether was added until 
precipitation began.  The suspension was left at 4°C for 16 h to yield further solid that was 
collected by centrifugation then dried under reduced pressure to yield the desired product as a 
yellow powder (38 mg, 0.049 mmol, 55 %).  Compound 2 is water soluble (>25 mM), was stable 
over 4 months stored under N2 at -18°C and is stable in aqueous solution for several days (>72 
h);  1H NMR (400 MHz, D2O) δ 5.96 (m, 4H, Ar), 4.59 (s, 6H, PTA), 4.18 (s, 8H, PTA and -
CH2-O-), 3.08-3.13 (m, 4H, 2 x –CH2NHCO-), 2.61 (s, 4H, -CH2-CH2-CO-), 2.20-2.33 (m, 6H), 
2.08 (s, 3H, -CH3), 1.43-1.61 (m, 7H), 1.20 (m, 2H), 0.97 (m, 2H);
 31P{1H} NMR (D2O, 162 
MHz): δ = -33.4;  13C NMR (101 MHz, D2O) δ 173.6, 166.0, 158.7, 100.2, 98.7, 96.4, 88.5 (d, 
2C, J = 3.0 Hz, Ar), 87.7 (d, 2C, J = 3.0 Hz Ar), 70.7 (d, 3C, J = 6.0 Hz, PTA), 63.5, 48.6 (d, 3C, 
J = 15.0 Hz), 40.3, 39.2, 35.7, 28.7, 28.3, 27.9, 23.3, 20.8, 19.8, 17.3; HRMS (ES+) m/z found 
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772.2440 [M + H]+ C34H49N5O7PRu requires 772.2423.  LCMS (Vydac C18 5 mm (218TP54), 
4.6x150 mm (Waters) column): tR = 16.2 min. 
Compound 4:  TBTU (274 mg, 0.853 mmol) and DIPEA (247 μl, 1.418 mmol) was added to a 
solution of 2-(2-(2-methoxyethoxy)ethoxy)acetic acid (152 mg, 0.853 mmol) in DMF (1 ml) 
under an atmosphere of N2 and stirred for 20 min.  The solution was then added to a suspension 
of 3 (179 mg, 0.704 mmol) in DMF (3 ml) then stirred.  After 18 h a further TBTU (374 mg, 
1.16 mmol) and 2-(2-(2-methoxyethoxy)ethoxy)acetic acid (152 mg, 0.853 mmol) was added 
followed by reduction of the solvent volume to 1.5 ml under vacuum and stirring for a further 24 
h.  The reaction mixture was dried under reduced pressure, diluted by the addition of DCM (50 
ml), extracted with H2O (2 x 20 ml) followed by drying of the organic layer with Na2SO4.  The 
organic layer was concentrated to 5 ml then directly loaded onto a silica gel column (25 g) and 
the crude product was isolated (DCM and 2% MeOH).  The residue was then further purified via 
column chromatography on silica gel (80 g) (DCM (100%) to DCM and MeOH (2%)).  The 
eluted product fractions were collected and subject to a further column chromatography on silica 
gel (80 g) (DCM (100%) to DCM and MeOH (2%)) to yield the product as an orange-red solid 
(100 mg, 0.241 mmol, 34 %); RF (silica, DCM-MeOH, 90:10) : 0.37;
 1H NMR (CDCl3, 400 
MHz): δ = 9.14 (s, 1H, amide NH), 8.82 (d, J = 5.0 Hz, 2H), 8.69 (s br, 2H), 8.33 – 8.29 (m, 
2H), 8.01 (d, J = 8.5 Hz, 1H), 7.36 (t, J = 5.0 Hz, 1H), 4.13 (s, 2H, -O-CH2-CONH-), 3.85 – 3.54 
(m, 8H, 2 x –O-CH2CH2-O-), 3.36 (s, 3H, CH3), 1.88 (m, 1H); 13C{1H}  NMR (CDCl3, 101 
MHz): δ = 169.3, 157.5, 156.4, 146.1, 145.7, 142.5, 140.0, 135.9, 127.6, 121.8, 121.6, 71.8, 
71.5, 71.0 , 70.4, 70.2, 59.1; HRMS (ES+) m/z found 437.1674 [M + Na]+ C18H22N8O4Na 
requires 437.1662, m.p. 105 - 107 °C. 
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Compound 5:  4 (84 mg, 0.203 mmol) was suspended in anhydrous toluene (10 ml) and 2,3-
dichloro-5,6-dicyano-p-benzoquinone (92 mg, 0.405 mmol) was added.  The suspension was 
stirred for 1 h at 120°C followed by evaporation of the solvent under reduced pressure.  The 
desired product was isolated by column chromatography on silica gel (80 g) (DCM (100 %) to 
DCM and MeOH (98:2) over 7 minutes then to DCM and MeOH (94:6) at 40 minutes) as a pink 
powder (56 mg, 0.136 mmol, 67 %).  5 is soluble in H2O at a concentration of >24 mM; RF 
(silica, DCM-MeOH, 90:10) : 0.5;  1H NMR (CDCl3, 400 MHz): δ = 9.37 (s, 1H, amide NH), 
9.14 (d, J = 5.0 Hz, 2H, Ar), 9.01 (d, J = 2.5 Hz, 1H, Ar), 8.80 (d, J = 8.5 Hz, 1H, Ar), 8.66 (dd, 
J = 8.5, 2.5 Hz, 1H, Ar), 7.59 (t, J = 5.0 Hz, 1H, Ar), 4.20 (s, 2H, -O-CH2-CONH-), 3.86 – 3.58 
(m, 8H, 2 x –O-CH2CH2-O-), 3.37 (s, 3H, CH3); 13C{1H}  NMR (CDCl3, 101 MHz): δ = 169.8, 
163.5 x 2, 159.7, 158.6, 150.4, 144.8, 142.6, 137.6, 127.4, 125.8, 122.6, 71.8, 71.6, 70.8, 70.5, 
70.1; HRMS (ES+) m/z found 435.1516 [M + Na]+ C18H20N8O4Na requires 435.1505, m.p. 146 - 
149 °C ; HPLC (Agilent Hi-Plex H, 300*7.7 column): tR = 8.2 min. 
Compound 6:  3,6,9-trioxaundecanedioic acid (186 mg, 0.837 mmol) was added to a solution of 
DIPEA (0.56 ml, 3.22 mmol) in DMF (1 ml) and stirred at room temperature for 5 min followed 
by the addition of TBTU (646 mg, 2.01 mmol).  The solution was stirred for 30 min followed by 
the addition of 3 (426 mg, 1.68 mmol); the suspension was stirred for 19 h then dried under 
reduced pressure.  The resulting solid was purified by column chromatography on silica gel 
(DCM to 12% MeOH) to yield the desired product as a sticky orange solid (258 mg, 0.372 
mmol, 44 %); RF (silica, DCM-MeOH, 93 :7) : 0.2;  
1H NMR (400 MHz, CDCl3) δ 8.84 (m, 6H, 
Ar and amide NH), 8.59-8.64 (m, 4H, Ar and NH), 8.32 (s, 2H, NH), 8.25 (dd, 2H, J = 8.5, 2.5 
Hz, Ar), 7.98 (d, 2H, J = 8.5 Hz, Ar), 7.36 (t, 2H, J = 5.0 Hz, Ar), 4.16 (s, 4H, -O-CH2-CONH-), 
3.82 (s, 8H, -O-CH2-CH2-O-); 
13C NMR (101 MHz, CDCl3) δ 168.5, 157.5, 156.4, 145.9, 145.7, 
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142.9, 139.6, 135.5, 127.6, 122.0, 121.6, 71.1 70.7, 70.5; HRMS (ES+) m/z found 695.2676 [M + 
H]+ C30H31N16O5 requires 695.2664. 
Compound 7:  6 (259 mg, 0.373 mmol) and DDQ (347 mg, 1.53 mmol) were suspended in 
toluene (18 ml) and the mixture heated at reflux for 3 h.  The red suspension was dried under 
reduced pressure and the desired product isolated by column chromatography on silica gel (100 
% DCM to 20 % MeOH) as a dark red powder (94 mg, 0.136 mmol, 36 %).  7 is soluble in H2O 
at a concentration of >1 mM; RF (silica, DCM-MeOH, 85 :15) : 0.45; 
1H NMR (400 MHz, 
DMSO-d6) δ 10.35 (s, 2H, amide NH), 9.17 (d, 4H, J = 5.0 Hz, Ar), 9.12 (d, 2H, J = 2.5 Hz, Ar), 
8.62 (d, 2H, J = 8.5 Hz, Ar), 8.47 (dd, 2H, J = 8.5, 2.5 Hz, Ar), 7.82 (t, 2H, J = 5.0 Hz, Ar), 4.24 
(s, 4H, -O-CH2-CONH-), 3.75 (d, 8H, -O-CH2-CH2-O-); 
13C NMR (101 MHz, DMSO-d6) δ 
169.6, 162.7, 162.6, 159.0, 158.4, 144.0, 141.9, 137.8, 126.8, 125.1, 122.9, 70.4, 70.2, 69.7; 
HRMS (ES+) m/z found 691.2349 [M + H]+ C30H27N16O5 requires 691.2350; m.p. 187 °C; HPLC 
(Agilent Hi-Plex H, 300*7.7 column): tR = 10.1 min. 
General procedure for the non-isolated preparation of 8/9: For NMR studies 8 was prepared 
through the incubation of 2 (12 mM) and 5  (1 eq.) in PBS (50 mM, D2O, pD 7.65, 298 K).  9 
was also prepared through the incubation of 5 (7.2 mM) and 7 (0.5 eq.) in PBS (50 mM, D2O, pD 
7.65, 298 K).  For cell studies stock solutions of 8 and 9 were prepared through the co-incubation 
of 2 (200 μM) and 5 (1 eq.) or 7 (0.5 eq.) in H2O at 310 K for 12 h then analysed with ESI-MS.  
These solutions were used without further isolation/purification; HRMS (ES+) of 8 m/z found 
589.6945 [M + H + Na]2+ C52H69N11O11PRuNa requires 589.6923; HRMS (ES
+) of 9 m/z found 
726.5654 [M + 3H]3+ C98H125N22O19P2Ru2 requires 726.5679. 
Cell culture and inhibition of cell growth: The A2780 cell line was obtained from the 
European Collection of Cell Cultures (ECACC) (Salisbury, UK).  RPMI-1640 media and 
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penicillin streptomycin solution were obtained from Life Technologies, fetal bovine serum (FBS) 
was obtained from Sigma.  Cells were cultured in RPMI-1640 with GlutaMAX media containing 
10% FBS and penicillin at 37°C and 5% CO2. Cytotoxicity was determined using the MTT 
assay.28 Cells were seeded in flat-bottomed 96-well plates by the addition of cells as a suspension 
in media containing 10% FBS (100 μl per well, approximately 4300 cells) and pre-incubated for 
24 h.  Preformed stock solutions of 8 and 9 were prepared as described previously, all other stock 
solutions were prepared in H2O immediately prior to use.  Stock solutions were then diluted by 
the addition to the culture medium then sequentially diluted to yield compound solutions of the 
required concentrations.  Aliquots (100 µl) of these stock solutions were added to plate wells to 
yield final compound concentrations in the range 0 µM to 100 µM/400 µM.  The 96-well plates 
were then incubated for a further 72 h followed by the addition of MTT (3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) solution (20 μl, 5 mg/mL in H2O) to each well 
and the plates incubated for a further 2 h.  The culture medium was then aspirated and the 
formazan precipitate produced by mitochondrial dehydrogenases of living cells was dissolved by 
the addition of DMSO (100 μl) to each well. The absorbance of the resultant solutions at 590 nm, 
which is directly proportional to the number of surviving cells, was recorded using a microplate 
reader. The percentage of surviving cells was determined by measurement of the absorbance of 
wells corresponding to untreated control cells. The reported IC50 values are based on the mean 
values from three independent experiments; each concentration level per experiment was 
evaluated in triplicate, and those values are reported in Table 1. 
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SYNOPSIS  
The strain-promoted cycloaddition between a RuII organometallic compound, functionalised at 
the arene ligand with a bicyclononyne derivative, and a di-tetrazine, yields the formation of a 
dinuclear organometallic compound in biological media.  The dinuclear compound exhibits 
increased cytotoxicity against tumorigenic cells relative to its constituent components, yielding a 
novel route toward their cytotoxic activation in cellulo. 
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